<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02868801</url>
  </required_header>
  <id_info>
    <org_study_id>HRPRBL-PHN</org_study_id>
    <nct_id>NCT02868801</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Pregabalin Sustained Release Tablet for Postherpetic Neuralgia</brief_title>
  <acronym>EASOPSRTFP</acronym>
  <official_title>Efficacy and Safety of Pregabalin Sustained Release Tablet for Postherpetic Neuralgia -A Multicenter,Randomized, Double-blind, Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the Efficacy and safety of pregabalin sustained
      release tablet versus placebo for postherpetic neuralgia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, multicenter, placebo-controlled trial to compare the
      efficacy and safety of pregabalin SR vs placebo in patients with PHN.

      The study is conducting at 27 study centers in China. Patients were randomized to receive
      pregabalin, starting at 165 mg/day and increasing to a maintenance dose of 330 or 660 mg/day,
      or placebo.

      The study includes a 1-week, single-blind, placebo run-in period; a 2-week
      dose-escalation/optimization phase; a 12-week, fixed-dose treatment period; and a 1-week
      taper phase.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Responders</measure>
    <time_frame>15 weeks</time_frame>
    <description>A responder is defined as a subject with a 30% reduction in weekly mean pain score from baseline to endpoint</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>50% reduction in weekly mean pain score from baseline to study completion</measure>
    <time_frame>15 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Mean Pain Scores from study completion to baseline</measure>
    <time_frame>15 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Mean Sleep Interference Scores from study completion to baseline</measure>
    <time_frame>15 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Postherpetic Neuralgia</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo, oral administration for 14 weeks (2 week titration and 12-week fixed dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pregabalin SR tablet 165mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1pills once ,one time a day in an hour after meals, oral administration for 14 weeks (2 week titration and 12-week fixed dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pregabalin SR tablet 330mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1pills once ,one time a day in an hour after meals, oral administration for 14 weeks (2 week titration and 12-week fixed dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pregabalin SR tablet 660mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2pills once ,one time a day in an hour after meals, oral administration for 14 weeks (2 week titration and 12-week fixed dose)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>same intervention as the experimental group</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo tablet of pregabalin sustained release tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin SR tablet 165mg/day</intervention_name>
    <description>According to the efficacy and safety in titration</description>
    <arm_group_label>Pregabalin SR tablet 165mg/day</arm_group_label>
    <other_name>Pregabalin sustained release tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin SR tablet 330mg/day</intervention_name>
    <description>According to the efficacy and safety in titration</description>
    <arm_group_label>Pregabalin SR tablet 330mg/day</arm_group_label>
    <other_name>Pregabalin sustained release tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin SR tablet 660mg/day</intervention_name>
    <description>According to the efficacy and safety in titration.</description>
    <arm_group_label>Pregabalin SR tablet 660mg/day</arm_group_label>
    <other_name>Pregabalin sustained release tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Outpatient ，Patients can not stay in the hospital overnight；

          2. Patients must have pain present for more than 3 months after the healing of the herpes
             zoster skin rash；

          3. At least 4 days and at least 8 pain diaries(Pain Numeric Rating Scale) must be
             completed satisfactorily within the seven days of single-blind, placebo run-in period,
             and the average pain score must be greater than or equal to 4；

          4. At screening (V0) and enrollment (V1), patients must have a score of greater than or
             equal to 40 mm on the 100 mm pain visual analog scale；

          5. Women were neither pregnant nor lactating, and those of childbearing age had a
             confirmed negative serum pregnancy test at baseline and practiced an appropriate
             method of contraception throughout the study.

        Exclusion Criteria:

          1. Decrease of ≥30% on their pain VAS or ≥ 4 between any two pain diaries during the
             placebo run-in period.( in order to remove potential placebo-responders)；

          2. Patients who had failed to respond to previous treatment for PHN with gabapentin at
             doses ≥1200 mg/day ；

          3. History of using pregabalin or participation in a previous trial of pregabalin；

          4. Patients with a skin condition or severe non-PHN pain that might impair the self
             assessment of pain caused by PHN；

          5. Patients with other Nervous system disorders which might impair completing the pain
             diaries or sleep interference diaries；

          6. History of epilepsy and being treated by drug therapy；

          7. Previous surgical therapy for PHN；

          8. History of using effective therapies during 2 weeks before screening (V0),eg:
             acupuncture and moxibustion, Transcutaneous Electrical Nerve Stimulation；

          9. Potentially retinal toxicity of drugs past or now；

         10. Prohibited medications without appropriate washout；

         11. Malignancy within the past 2 years；

         12. Laboratory examination: WBC＜2.5×109/L；ANC＜1.5×109/L；PLT＜100×109/L；ALT/AST＞3ULN；

         13. Creatinine clearance ≤ 60 mL/min；

         14. Positive antibody of Hepatitis c，Human immunodeficiency virus ，Treponema pallidum ；

         15. Patients who are allergic to or intolerant of pregabalin or other drugs which have a
             similarly chemical structure ；

         16. History of illicit drug or alcohol abuse within the last 2 years；

         17. Clinically significant or unstable hepatic, respiratory, or hematologic illnesses or
             psychologic conditions; unstable cardiovascular disease which may increase the risk of
             participation the clinical trial in the opinion of the study investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lu Qianjin, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Central South University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Liang Yunsheng, M.D.</last_name>
    <phone>UN</phone>
    <email>liangyunsheng@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lu Qianjin, M.D.</last_name>
    <phone>13787097676</phone>
    <email>qianlu5860@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Anhui Medical University</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beijing Chao-yang Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beijing Friendship Hospital ,Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>China-Japan Friendship Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fujian Medical University Union Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sun Yat-Sen Memory Hospital , Sun Yat-Sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Guizhou Medical University</name>
      <address>
        <city>Guiyang</city>
        <state>Guizhou</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Hainan Medical College</name>
      <address>
        <city>Haikou</city>
        <state>Hainan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fourth Hospital Of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Second Hospital Of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Second Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Third Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yancheng City NO.1 People's Hospital</name>
      <address>
        <city>Yancheng</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shengjing Hospital Of China Medical University</name>
      <address>
        <city>Shengyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The People's Hospital of Liaoning Province</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Qingdao Municipal Hospital(Group)</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>First Hospital Of Shanxi Medical University</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Second Hospital Of Shanxi Medical University</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Xijing Hospital; the Fourth Military Medical University</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>People's Hospital of Xinjiang Uygur Autonomous Region</name>
      <address>
        <city>Wulumuqi</city>
        <state>Xinjiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Xinjiang Uygur Autonomous Region Hospital OF TCM</name>
      <address>
        <city>Wulumuqi</city>
        <state>Xinjiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Kunming Medical University</name>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hangzhou First People's Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital , Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>van Seventer R, Feister HA, Young JP Jr, Stoker M, Versavel M, Rigaudy L. Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: a 13-week, randomized trial. Curr Med Res Opin. 2006 Feb;22(2):375-84.</citation>
    <PMID>16466610</PMID>
  </results_reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2015</study_first_submitted>
  <study_first_submitted_qc>August 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2016</study_first_posted>
  <last_update_submitted>August 11, 2016</last_update_submitted>
  <last_update_submitted_qc>August 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pregabalin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Neuralgia, Postherpetic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregabalin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

